Table 1.
Participant demographic and clinical characteristics.
| Variable | Healthy volunteers (HV) | Treatment-resistant depression (TRD) |
|---|---|---|
| Total number in sample | 21 (13 female, 8 male) | 29 (18 female, 11 male) |
| Age in years | 35 (±11) | 36 (±10) |
| BMI in kg/m2 | 27.8 (±4.6) | 26.4 (±5.7) |
| Length of illness | 21 (±11) years | |
| Length of current episode | 45 (±73) months | |
| Number of failed treatments | 6 (±3) adequate trials | |
| Baseline MADRS score | 1 (±2) | 33 (±5) |
| Baseline SHAPS score | 18 (±4) | 40 (±4) |
| Baseline TEPS-anticipatory score | 47 (±6) | 23 (±8) |
| Baseline TEPS-consummatory score | 40 (±5) | 23 (±5) |
| Figs. 1–3 & 4A: Number of post-ketamine fMRI images | 20 (12 female, 8 male) | 26 (16 female, 10 male) |
| Figs. 1–3 & 4A: Number of post-placebo fMRI images | 17 (11 female, 6 male) | 25 (13 female, 12 male) |
| Fig. 4B, C: Number of subjects with both fMRI and SHAPS/TEPS data, both post-ketamine and post-placebo | 11 (5 female, 6 male) | |
| Fig. 5A, B: Number of subjects with fMRI and SHAPS data post-ketamine | 15 (9 female, 6 male) | |
| Fig. 5A: Number of subjects with fMRI and SHAPS data post-placebo | 12 (6 female, 6 male) |
(± standard deviation, where relevant).